Grant to aid nanotechnology training

JOHNSTOWN - Fulton-Montgomery Community College will use federal grant money to help train people in nanotechnology.

The program, which is still being designed, will help workers who lost their jobs as a result of increased imports or shifts in production out of the United States. The program also will help unemployed veterans.

"What we are looking to do is find a way to put together a one-year program in nanotechnology and get them ready for a new job, versus our typical two-year curriculum," FMCC President Dustin Swanger. "I expect this could help 50 or more students locally over the next two years."

A Fulton-Montgomery Community College student works on the Atomic Force Microscope in May at FMCCs clean room classroom. The Leader-Herald/Amanda Whistle

The college will receive nearly $100,000 from the federal government for the job-training program.

Swanger said the program will be designed to aid people that have technology backgrounds and out of work by adding to their existing knowledge in the field. As a result, this program will only be offered to those with experience and not brand new, incoming students.

Swanger said he hopes to have the program available to the community by the fall semester next year.

Richard Prestopnik, a professor of electrical technology at the college, will head the program.

"Part of the funding is to allow us to do some curriculum development work," Prestopnik said. "We are concentrating on nanotechnologies and semiconductor manufacturing. We are attempting to design a program that will grant a one-year certificate targeted toward individuals with experience in advanced technical fields."

He said the course will include a lot of hands-on work so students can be prepared for what it will be like in the actual job.

Read more:
Grant to aid nanotechnology training

Industrial Nanotech, Inc. Signs Exclusive Agreement with Boral Roofing, LLC

NAPLES, Fla.--(BUSINESS WIRE)--

Industrial Nanotech, Inc. (Pink Sheets: INTK), an emerging global leader in nanotechnology based energy saving and sustainable solutions announced today that the Company has signed an agreement granting Boral Roofing, LLC the exclusive rights to market Nansulate(R) Crystal, the Companys patented clear roof coating, in the US, Canada, Mexico, and the Caribbean. Nansulate(R) Crystal is manufactured and sold exclusively by Industrial Nanotech, Inc.

We look forward to working with Boral Roofing, LLC to make the benefits of Nansulate(R) Crystal, combined with the extraordinary performance qualities and aesthetic beauty of concrete roof tile, the standard for fine quality roofs, states Francesca Crolley, VP of Business Development for Industrial Nanotech, Inc.

About Boral Roofing:

Boral Roofing LLC is a subsidiary of Boral USA, the country's largest premium provider of complete roofing and re-roofing solutions for architects as well as commercial and residential builders. Boral Roofing operates 15 clay and concrete tile manufacturing plants throughout the U.S. and Mexico.

About Boral USA:

Headquartered in Roswell, Georgia, Boral USA is a leading manufacturer in the building material industry. Boral USA's subsidiaries include Boral Bricks: #1 manufacturer of brick in the United States, Boral Roofing: the nation's leading manufacturer of clay and concrete roof tiles, Boral Stone Products, manufacturer of Cultured Stone: #1 Brand of manufactured stone veneer, Boral Composites Inc., manufacturer of Boral TruExterior Trim: #1 Brand of poly-ash exterior trim products.

About Nansulate(R)

Nansulate(R) is the Company's patented product line of award winning, specialty coatings containing a nanotechnology based material that provides the combined performance qualities of thermal insulation, corrosion prevention, resistance to mold growth, chemical resistance and lead encapsulation in an environmentally safe, water-based, coating formulation.

About Industrial Nanotech Inc.

Read the rest here:
Industrial Nanotech, Inc. Signs Exclusive Agreement with Boral Roofing, LLC

CMU to build 2 medical school buildings in Saginaw

SAGINAW (WJRT) -

(10/04/12) - Saginaw will be home to two new medical school buildings in the coming years.

Central Michigan University unveiled drawings of the two buildings that will be part of CMU's new medical school. One building adjacent to Covenant Healthcare on the west side of the city, and the other near St. Mary's of Michigan, on the west side.

CMU decided on two sites that will feature two different medical trainings. Construction could begin next fall.

"The issue is really for people in our area having access to health care, physicians are one of the key players," said Dr. Ernie Yoder, CMU College of Medicine dean.

But Yoder says the school, which has already received more than 2,000 applications, will do more than develop doctors.

"So we are partnering with other health professions to make sure we do inter-professional team training, etcetera so that we attract and keep the other partners for the health care team," he said.

CMU has raised more than $16.4 million for the medical school.

"People have been forthcoming on that decision because they know the impact this will have on our community," said Doug Iles, CMU foundation development.

Now that the drawings have been unveiled, the school expects to reach its goal of $25 million.

Excerpt from:
CMU to build 2 medical school buildings in Saginaw

Smaller estrogen doses improve mood without memory loss

Madison, Wisconsin - Ten years ago, the landmark Womens Health Initiative (WHI) revealed that women older than 65 increased their risk for memory loss if they took estrogen to relieve the symptoms of menopause.

But new research by the University of Wisconsin School of Medicine and Public Health (SMPH) suggests that estrogen given in smaller doses to younger women just entering menopause does not worsen memory and improves mood and symptoms of depression.

The School of Medicine and Public Health was a participant in the Kronos Early Estrogen Prevention Study (KEEPS), which was conducted and supported by the Kronos Longevity Research Institute in Phoenix, Arizona. KEEPS-Cog (Cognitive and Affective Study) is an ancillary study measuring cognitive and emotional outcomes, funded by the National Institute on Aging at the National Institutes of Health (NIH).

Dr. Sanjay Asthana, the lead researcher of the cognitive and affective (emotional) part of the study and professor of medicine (geriatrics) at the UW School of Medicine and Public Health, presented the findings today during the North American Menopause Society annual meeting in Orlando, Florida. The preliminary findings, which are not yet peer-reviewed, will be submitted for publication in a medical journal.

The KEEPS-Cog was a four-year study and involved 662 women (average age 52.7 years) of the 727 women in theKronos Early Estrogen Prevention Study cohort.

See the article here:
Smaller estrogen doses improve mood without memory loss

Cabrera wears the Crown

KANSAS CITY (AP) Miguel Cabrera had just achieved baseball immortality, and everyone around him knew it.

Tigers Manager Jim Leyland had tears welling in his eyes. General Manager Dave Dombrowski kept trying to remind people to stop and enjoy the moment. Prince Fielder simply shook his head in disbelief at the history that had unfolded.

Less than an hour earlier, in the midst of Detroit's otherwise meaningless 1-0 victory over Kansas City, it had finally become official: Cabrera had won the Triple Crown.

"Everybody said to me it was unbelievable. They were all excited to see this, enjoy this, be a part of something big," he said, taking the rare feat in stride better than anyone.

Cabrera finished the regular season hitting .330 with 44 homers and 139 RBI, leading the American League in all three statistical categories, making him just the 15th player to achieve the Triple Crown and the first since Boston's Carl Yastrzemski in 1967.

"I've managed a lot of players, managed some great ones, but I've never seen anything like this," Leyland said.

Among those in one of baseball's most exclusive clubs are Lou Gehrig, Ted Williams, Mickey Mantle and Frank Robinson.

Cabrera's achievement wasn't assured until the Yankees pinch-hit for Curtis Granderson in their 14-2 rout of the Boston Red Sox. Granderson had homered twice to reach 43 for the year, tied with the Rangers' Josh Hamilton and one shy of the Tigers' third baseman.

The closest competition in the race for the batting title was Angels rookie Mike Trout, who remains Cabrera's toughest competition for the AL MVP. Cabrera was the runaway leader in RBI.

"When he's over the plate, he can do anything. He's the best hitter in the game," Trout said.

See the rest here:
Cabrera wears the Crown

Miguel Cabrera wins 1st Triple Crown in 45 years

Enlarge Photo

KANSAS CITY, Mo. Miguel Cabrera had just achieved baseball immortality, and everyone around him knew it.

Tigers manager Jim Leyland had tears welling in his eyes. General manager Dave Dombrowski kept trying to remind people to stop and enjoy the moment. Prince Fielder simply shook his head in disbelief at the history that had unfolded.

Less than an hour earlier, in the midst of Detroits otherwise meaningless 1-0 victory over Kansas City, it had finally become official: Cabrera had won the Triple Crown.

Everybody said to me it was unbelievable. They were all excited to see this, enjoy this, be a part of something big, he said, taking the rare feat in stride better than anyone.

Cabrera finished the regular-season hitting .330 with 44 homers and 139 RBIs, leading the American League in all three statistical categories, making him just the 15th player to achieve the Triple Crown and the first since Bostons Carl Yastrzemski in 1967.

Ive managed a lot of players, managed some great ones, but Ive never seen anything like this, Leyland said. When youre sitting back and its over with, people are talking about Miguel Cabrera, the rest of the world will have no idea who his manager was, but I will.

Among those in one of baseballs most exclusive clubs are Lou Gehrig, Ted Williams, Mickey Mantle and Frank Robinson, who called it an incredible accomplishment for a gifted young man, and Miguel should be proud of his all-around excellence and consistency throughout the season.

Cabreras achievement wasnt assured until the Yankees pinch-hit for Curtis Granderson in their 14-2 rout of the Boston Red Sox. Granderson had homered twice to reach 43 for the year, tied with the Rangers Josh Hamilton and one shy of the Tigers third baseman.

The closest competition in the race for the batting title was Angels rookie Mike Trout, who remains Cabreras toughest competition for the AL MVP. Cabrera was the runaway leader in RBIs.

View original post here:
Miguel Cabrera wins 1st Triple Crown in 45 years

Baseball Immortality

KANSAS CITY, Mo. Miguel Cabrera had just achieved baseball immortality, and everyone around him knew it.

Tigers manager Jim Leyland had tears welling in his eyes. General manager Dave Dombrowski kept trying to remind people to stop and enjoy the moment. Prince Fielder simply shook his head in disbelief at the history that had unfolded.

Less than an hour earlier, in the midst of Detroit's otherwise meaningless 1-0 victory over Kansas City, it had finally become official: Cabrera had won the Triple Crown.

"Everybody said to me it was unbelievable. They were all excited to see this, enjoy this, be a part of something big," he said, taking the rare feat in stride better than anyone.

Cabrera finished the regular-season hitting .330 with 44 homers and 139 RBIs, leading the American League in all three statistical categories, making him just the 15th player to achieve the Triple Crown and the first since Boston's Carl Yastrzemski in 1967.

"I've managed a lot of players, managed some great ones, but I've never seen anything like this," Leyland said. "When you're sitting back and it's over with, people are talking about Miguel Cabrera, the rest of the world will have no idea who his manager was, but I will."

Among those in one of baseball's most exclusive clubs are Lou Gehrig, Ted Williams, Mickey Mantle and Frank Robinson, who called it "an incredible accomplishment for a gifted young man, and Miguel should be proud of his all-around excellence and consistency throughout the season."

Cabrera's achievement wasn't assured until the Yankees pinch-hit for Curtis Granderson in their 14-2 rout of the Boston Red Sox. Granderson had homered twice to reach 43 for the year, tied with the Rangers' Josh Hamilton and one shy of the Tigers' third baseman.

The closest competition in the race for the batting title was Angels rookie Mike Trout, who remains Cabrera's toughest competition for the AL MVP. Cabrera was the runaway leader in RBIs.

"When he's over the plate, he can do anything. He's the best hitter in the game," Trout said. "I think his approach, the way he battles with two strikes you leave one pitch over the plate that at-bat and he's going to hit it. He had an unbelievable year."

Read this article:
Baseball Immortality

Study Details Stresses Tied to Fertility Treatments

By Rick Nauert PhD Senior News Editor Reviewed by John M. Grohol, Psy.D. on October 4, 2012

A new EU study provides a comprehensive evaluation of the different stress points that challenge women as they struggle to become pregnant.

Researchers looked at the stress of not being able to naturally conceive and the stress associated with the difficult decision to undergo and then receive fertility treatments.

In the study, published in the journal Human Reproduction, researchers examined experiences of patients in four countries with the highest number of cases of assisted reproduction cycles in Europe: France, Germany, Italy and Spain.

Researchers acknowledge that the inability to normally conceive is extremely stressful for women who want to have a family.

Infertility causes a series of varied emotions that have a negative impact on important aspects of a womans life, said Dr. Juan Garca Velasco, one of the authors of the study. It is linked to depression, anxiety, anger, cognitive imbalance and low self-esteem.

Researchers analyzed the emotional impact of infertility and also identified aspects of fertility treatments that contribute to the physical and psychological stress suffered by many women.

Investigators studied 445 women, between the ages of 18 and 44 years, who were experiencing difficulties in conceiving. While some had never undergone any fertility treatment, others were receiving it at the time or had already received it in the past two years.

Almost one-third of the participants said they began to worry from the momentthey started trying to get pregnant, and nearly half claimed to have felt ashamed or like a failure as a woman.

Researchers determined that anxiety toward injections and the deterioration of their relationship with their partner were the main causes of stress for the women.

See the rest here:
Study Details Stresses Tied to Fertility Treatments

Mouse stem cells used to produce eggs, Japanese scientists say

Reaching a long-sought milestone, Japanese researchers have demonstrated in mice that eggs and sperm can be grown from stem cells and combined to produce healthy offspring, pointing to new treatments for infertility.

If the achievement can be repeated in humans and experts said they are optimistic that such efforts will ultimately succeed the technique could make it easier for women in their 30s or 40s to become mothers. It could also help men and women whose reproductive organs have been damaged by cancer treatments or other causes.

About one in 10 American women of childbearing age have trouble becoming or staying pregnant, and more than one-third of infertile couples must contend with a medical problem related to the prospective father, according to the national Centers for Disease Control and Prevention in Atlanta.

Using current technology, only about one-third of attempts at assisted reproduction result in live births, CDC data show. Scientists, doctors and patients would like to boost that percentage.

"These studies provide that next level of evidence that in the future fertility could be managed with stem cell intervention," said Teresa Woodruff, chief of fertility preservation at Northwestern University Feinberg School of Medicine.

The prospect of using stem cells to grow new eggs is particularly tantalizing, since women are born with a set number and don't make more once they are gone. In a sense, the therapy would allow them to turn back their biological clocks, said Stanford stem cell researcher Renee A. Reijo Pera, who studies reproduction.

"This is a get-them-back strategy," she said.

Dr. Mitinori Saitou and colleagues at Kyoto University detailed how they generated the functional mouse eggs in a report published online Thursday by the journal Science. Last year, the researchers reported in the journal Cell that they had done the same thing with mouse sperm.

In both cases, the team started with embryonic stem cells, which have the potential to develop into all of the different types of cells in the body.

The scientists exposed the embryonic stem cells to stimuli that coaxed them to become egg and sperm precursors.

See the article here:
Mouse stem cells used to produce eggs, Japanese scientists say

Warning: Genetically Modified Humans

ANATOLIA, 9,000BC - The rising sun advanced over the hills, engulfing the arid land in a blaze of warmth. Below the amber sky lay a patchwork of wheat fields, in which a scattering of stooped figures silently harvested their crops. Later, their harvest would be scrutinised, and only the largest grains selected for planting in the autumn. A revolution was occurring. For the first time in 3.6 billion years, life had subverted the evolutionary process and began to steer it not with natural selection, but artificial selection. Selection pressures became synonymous with the needs of the architects; the farmers. The technique led to a widespread transition from hunter-gathering to agriculture, a shift that would transform human culture and lay the foundations for the first civilisations. Moreover, in their efforts to permanently remodel the characteristics of a species, early farmers were pioneers of genetic modification. The modification of plants would later be followed by the domestication of animals, and perhaps eventually, human beings. From the promotion of eugenics to justify genocide in Nazi Germany, to the mass-produced and homogenous population of Aldous Huxley's dystopian future in the novel 'Brave New World', to 'Frankenfood', genetic engineering has amassed a reputation as a treacherous pursuit. However, a recent development appears to have slipped under the public radar: human pre-natal diagnosis. Screening foetal genomes to eliminate genetic 'defects' may lead to incremental changes in the human genetic reservoir, a permanent shift in our characteristics and eventually, self-domestication. The technique involves testing for diseases in a human embryo or foetus, and may be performed to determine if it will be aborted, or in high-risk pregnancies, to enable the provision of immediate medical treatment on delivery. Until recently, pre-natal screening required invasive procedures such as amniocentesis, in which the fluid from the sac surrounding the foetus, the amnion, is sampled and the DNA examined for genetic abnormalities. The procedure can only be performed after the 15th week of pregnancy, and carries a 1% risk of miscarriage and the possibility of complications. In the light of such limitations and risks, the technique hasn't gained widespread popularity. However, a research group based at the University of Washington in Seattle has developed an alternative. Their simple test can be performed weeks earlier than current pre-natal screening, and crucially, requires only a maternal blood sample and DNA from both parents. The technique exploits the fragments of foetal DNA in the mother's blood plasma, which can be strung together by sequencing each nucleotide many times, and then differentiated from maternal and paternal DNA by statistical comparison. It's quick, harmless, and may soon become widely available. Therein lies the problem. Such a tool is a powerful new route gleaning information about unborn offspring. The object of the exercise: to identify foetuses with the earmarks of genetic disease as candidates for abortion. Inevitably, the technique is vulnerable to abuse and will empower parents to discriminate the characteristics of their progeny pre-emptively, in a step towards 'designer babies'. Nevertheless, there is a more immediate concern. Screening for inheritable disorders requires knowledge of their genetic basis, which can be dangerously precarious. Some conditions, such as Down's syndrome; characterised by the presence of an extra chromosome, are glaringly obvious. Others have more subtle and complex genetic origins. Just as the invention of vaccines to prevent infectious diseases was followed by attempts at total eradication, our efforts to eliminate genetic characteristics may have permanent consequences. Autism spectrum disorder (ASD) has already been singled out as a potential target for the screening technology. The disorder, which is characterised by difficulties in communication and social interaction, and repetitive or stereotyped behaviours and interests, has a strong but elusive genetic basis. Intriguingly, there has been much speculation that the genes involved in the development of ASD may be linked to mathematical and scientific ability. The theory has roots in the overlap between certain useful aptitudes in technical professions, and behaviour typical of ASD. An obsessive attention to detail, the ability to understand predictable rule- based systems, 'systemising', and a narrow range of interests, are traits characteristic of both groups. Professor Baron Cohen of the University of Cambridge is a strong proponent of the idea, and has suggested that scientist couples are more likely to have children with the disorder. It's a compelling idea with intuitive plausibility, but the evidence isn't there (yet). Until we know better, perhaps restraint is needed in eliminating these potentially important genes from our gene pool. There has been speculation that Einstein and Newton were 'on the spectrum'- what if we inadvertently 'cured' the future world of similar talent? Will our descendants be less than human? Another candidate for remedy with reproductive technology is schizophrenia. The disorder affects cognition, and can lead to chronic problems with emotional responsiveness. The 1% prevalence of schizophrenia makes it an apt target for prevention. However, the globally consistent and high incidence of this disease may be an indicator of its association with advantageous genetic characteristics. The 'social brain hypothesis', the main theory to explain the evolution of schizophrenia, suggests that the human brain evolved to select for genes associated with schizophrenia in a trade for higher order cognitive traits. These include language and the ability to interpret the thoughts and emotions of others. Schizophrenia is the cost that humans pay for being able to communicate, and as such, the genes responsible may be an essential component of the human gene pool. As with ASD, the elimination of the disease may have unintended consequences, and permanently alter the social dynamics within our species. This mechanism, termed a 'heterozygote advantage', can arise from the benefits of carrying different forms of a gene, as opposed to two of the same variant, or 'alleles'. The phenomenon has been proposed for a wide variety of genetic diseases; however usefulness is often dependent on environmental context. Because human lifestyles have diversified to such an extent from those of our ancestors, certain advantages may be outdated. The malaria protection conferred by carrying a single sickle-cell gene is hardly worth the risk of debilitating anaemia if you end up with two- especially in a modern world where anti-malarial medication is widely available. The systematic eradication of this disorder, and many others, will be a welcome and significant medical advancement. But caution is needed. Following a recent project to build a comprehensive map of the functional elements in the human genome, ENCODE, a function was assigned to 80% of our DNA sequence. However, our genomes are still poorly understood. Many sequences are multi-functional, and knowledge of mechanisms of gene expression is essential to any meaningful model. We urgently need a regulatory framework for the use of procedures such as pre-natal screening, and to exercise restraint in gene eradication. A detailed assessment and forecast of the long- term consequences is essential before a potentially corrosive procedure become entrenched in modern society. The alternative: we might just end up domesticating ourselves. DNA image: Altered from original by Sponk on Wikimedia Commons.

Follow Scientific American on Twitter @SciAm and @SciamBlogs. Visit ScientificAmerican.com for the latest in science, health and technology news. 2012 ScientificAmerican.com. All rights reserved.

See the article here:
Warning: Genetically Modified Humans

2-day test can spot gene diseases in newborns

WASHINGTON (AP) -

Too often, newborns die of genetic diseases before doctors even know what's to blame. Now scientists have found a way to decode those babies' DNA in just days instead of weeks, moving gene-mapping closer to routine medical care.

The idea: Combine faster gene-analyzing machinery with new computer software that, at the push of a few buttons, uses a baby's symptoms to zero in on the most suspicious mutations. The hope would be to start treatment earlier, or avoid futile care for lethal illnesses.

Wednesday's study is a tentative first step: Researchers at Children's Mercy Hospital in Kansas City, Mo., mapped the DNA of just five children, and the study wasn't done in time to help most of them.

But the hospital finds the results promising enough that by year's end, it plans to begin routine gene-mapping in its neonatal intensive care unit - and may offer testing for babies elsewhere, too - while further studies continue, said Dr. Stephen Kingsmore, director of the pediatric genome center at Children's Mercy.

"For the first time, we can actually deliver genome information in time to make a difference," predicted Kingsmore, whose team reported the method in the journal Science Translational Medicine.

Even if the diagnosis is a lethal disease, "the family will at least have an answer. They won't have false hope," he added.

More than 20% of infant deaths are due to a birth defect or genetic diseases, the kind caused by a problem with a single gene. While there are thousands of such diseases - from Tay-Sachs to the lesser known Pompe disease, standard newborn screening tests detect only a few of them. And once a baby shows symptoms, fast diagnosis becomes crucial.

Sequencing whole genomes - all of a person's DNA - can help when it's not clear what gene to suspect. But so far it has been used mainly for research, in part because it takes four to six weeks to complete and is very expensive.

Wednesday, researchers reported that the new process for whole-genome sequencing can take just 50 hours - half that time to perform the decoding from a drop of the baby's blood, and the rest to analyze which of the DNA variations uncovered can explain the child's condition.

Read the rest here:
2-day test can spot gene diseases in newborns

Gene diseases in newborns spotted with 2-day test

Too often, newborns die of genetic diseases before doctors even know what's to blame. Now scientists have found a way to decode those babies' DNA in just days instead of weeks, moving gene-mapping closer to routine medical care.

The idea: Combine faster gene-analyzing machinery with new computer software that, at the push of a few buttons, uses a baby's symptoms to zero in on the most suspicious mutations. The hope would be to start treatment earlier, or avoid futile care for lethal illnesses.

Wednesday's study is a tentative first step: Researchers at Children's Mercy Hospital in Kansas City, Mo., mapped the DNA of just five children, and the study wasn't done in time to help most of them.

But the hospital finds the results promising enough that by year's end, it plans to begin routine gene-mapping in its neonatal intensive care unit and may offer testing for babies elsewhere, too while further studies continue, said Dr. Stephen Kingsmore, director of the pediatric genome center at Children's Mercy.

Even if the diagnosis is a lethal disease, "the family will at least have an answer. They won't have false hope," said Kingsmore, who team reported the method in the journal Science Translational Medicine.

More than 20 per cent of infant deaths are due to a birth defect or genetic diseases, the kind caused by a problem with a single gene. While there are thousands of such diseases from Tay-Sachs to the lesser known Pompe disease, standard newborn screening tests detect only a few of them. And once a baby shows symptoms, fast diagnosis becomes crucial.

Sequencing whole genomes all of a person's DNA can help when it's not clear what gene to suspect. But so far it has been used mainly for research, in part because it takes four to six weeks to complete and is very expensive.

Wednesday, researchers reported that the new process for whole-genome sequencing can take just 50 hours half that time to perform the decoding from a drop of the baby's blood, and the rest to analyze which of the DNA variations uncovered can explain the child's condition.

That's an estimate: The study counted only the time the blood was being decoded or analyzed, not the days needed to ship the blood to Essex, England, home of a speedy new DNA decoding machine made by Illumina, Inc. or to ship back the results for Children's Mercy's computer program to analyze. Kingsmore said the hospital is awaiting arrival of its own decoder, when 50 hours should become the true start-to-finish time.

Specialists not involved with the study said it signals the long-promised usefulness of gene-mapping to real-world medicine finally is close.

Read the original post:
Gene diseases in newborns spotted with 2-day test

Rapid gene-mapping test may diagnose disease in newborns

WASHINGTONToo often, newborns die of genetic diseases before doctors even know what's to blame. Now scientists have found a way to decode those babies' DNA in just days instead of weeks, moving gene-mapping closer to routine medical care.

The idea: Combine faster gene-analyzing machinery with new computer software that, at the push of a few buttons, uses a baby's symptoms to zero in on the most suspicious mutations. The hope would be to start treatment earlier, or avoid futile care for lethal illnesses.

Wednesday's study is a tentative first step: Researchers at Children's Mercy Hospital in Kansas City, Mo., mapped the DNA of just five children, and the study wasn't done in time to help most of them.

But the hospital finds the results promising enough that by year's end, it plans to begin routine gene-mapping in its neonatal intensive care unit -- and may offer testing for babies elsewhere, too -- while further studies continue, said Dr. Stephen Kingsmore, director of the pediatric genome center at Children's Mercy.

"For the first time, we can actually deliver genome information in time to make a difference," predicted Kingsmore, whose team reported the method in the journal Science Translational Medicine.

Even if the diagnosis is a lethal disease, "the family will at least have an answer. They won't have false hope," he added.

More than 20 percent of infant deaths are due to a birth defect or genetic diseases, the kind caused by a problem with a single gene. While there are thousands of such diseases -- from Tay-Sachs to the lesser known Pompe disease, standard newborn screening tests detect only a few of them. And once a baby shows symptoms, fast diagnosis becomes crucial.

Sequencing whole genomes - all of a person's DNA - can help when it's not clear what gene to suspect. But so far it has been used mainly for research, in part because it takes four to six weeks to complete and is very expensive.

Wednesday, researchers reported that the new process for whole-genome sequencing can take just 50 hours -- half that time to perform the decoding from a drop of the baby's blood, and the rest to analyze which of the DNA variations uncovered can explain the child's condition.

That's an estimate: The study counted only the time the blood was being decoded or analyzed, not the days needed to ship the blood to Essex, England, home of a speedy new DNA decoding machine made by Illumina, Inc. -- or to ship back the results for Children's Mercy's computer program to analyze. Kingsmore said the hospital is awaiting arrival of its own decoder, when 50 hours should become the true start-to-finish time.

Continue reading here:
Rapid gene-mapping test may diagnose disease in newborns

Chemistry Building marks a century

It was the first building on what is today Dals Studley campus. One hundred years later, the Chemistry Building is still standing as a centre for teaching, research and study.

Last Friday afternoon, faculty, staff, students and alumni gathered together to celebrate the buildings 100th anniversary. While the official anniversary of the start of construction was on August 15, event coordinators decided to incorporate this special milestone into Homecoming weekend.

The celebration was led by Department Chair Josef Zwanziger, who took alumni on a guided tour of the building, followed by a presentation on the buildings long-standing history.

Originally deemed the Science Building because it housed the department of chemistry, physics and geology, it was envisioned as the academic core of the campus. The project was realized by architect Frank Darling of Toronto, who surveyed the lot in 1911 and created a general campus plan. Darling chose a local architect, Andrew Randall Cobb, to design the buildings. Together, they decided on an 18th century Georgian style of architecture in keeping with other attractive buildings in Halifax such as Province House and Government House. The Georgian style was adaptable and would lend an inviting, domestic appearance to the campus. In his annual report of 1911/12, Dalhousie President Arthur Stanley MacKenzie praised the new building as "by far the largest and finest building for pure science east of McGill."

The Chemistry Building's cornerstone was laid on August 15, 1912 by the Governor General, the Duke of Connaught, in a ceremony attended by the High Commissioner for Australia, the premiers of Quebec and Nova Scotia and the Governor of Newfoundland. (See photo on left, via Dalhousie Archives and Special Collections.) Construction was funded by a Carnegie Corporation grant of $50,000, with Dalhousie required to raise an additional $40,000.

With Cobbs efforts, in conjunction with the input from science professors Eben Mackay and Howard Bronson, the final plans were completed in January of 1913. The building was finished by summer 1915, and Dals science programs moved from their home in Forrest Building.

The building was constructed of hard ironstone from Purcell's Cove, along with Portland cement. Originally, it was designed as two separate buildings in one, so that the hazardous fumes of the Chemistry department would be isolated. There was also space allotted to the Engineering and Geology departments, part of the building until 1945. Despite the building's integrity, on December 6, 1917 it was severely damaged in the Halifax Explosion. Repairs to doors, windows and the roof were extensive and cost almost $10,000, a sum readily paid by the Carnegie Corporation.

By 1960 after many years of construction and expansion some things never change at Dal it came to pass that Chemistry would occupy the entire building (the photo on the right is from 1937). In 1965, the building was joined to the adjacent Macdonald Memorial Library (now the Macdonald Building). The extension created 40,000 square feet of new floor space and added additional departmental offices, the university bookstore and a lecture hall. A $9.8 million extension and renovation in 1991 updated the building and facilities and added almost 23,000 square feet on the north side of the building, including new undergraduate laboratories.

Today, the Department of Chemistry has 26 professors, four emeritus professors, 13 adjunct professors, seven instructors, and 14 technical/administrative staff. It welcomes visiting scientists, postdocs and research assistants alongside its 70 graduate students, more than 40 honours students and 3,000-plus students who take undergraduate chemistry courses each year. Its facilities include the computer-aided learning laboratory, laser photolysis laboratories, the Nuclear Magnetic Resonance Research Resource, the Trace Analysis Research Centre, the Mass Spectrometry Laboratory and many other specialized facilities. Faculty and students carry out research in all areas of chemistry: analytical, bio-organic, computational, environmental, inorganic, materials, organic, physical and theoretical.

After the history tour, a ceremony was held outside the building allowing guests to reflect on this long legacy. Attendees included Leonard Preyra, minister of communities, culture and heritage, and Marilyn More, minister of labour and advanced education, both of whom offered their congrats on behalf of the Government of Nova Scotia.

See original here:
Chemistry Building marks a century

Lawmakers seek 'green chemistry' delay

Here's an interesting test case for California's much-debated business climate.

Last week, 17 lawmakers from Gov. Jerry Brown's own party asked him to put a hold on recently issued regulations that could "impact every manufacturer, business and consumer in California and beyond."

The regulations concern California's 2008 "green chemistry" law requiring businesses to identify and, where judged necessary and feasible, find alternatives to approximately 1,200 "chemicals of concern," like formaldehyde and lead, found in a wide range of products.

Chewed over for four years with input from business groups and environmental and health care advocates, the regulations were issued by the Department of Toxic Substances Control on July 27, subject to a final comment period.

"We see this as a two-for-one initiative," said Debbie Raphael, the department's director, in a news release. "Public health and the environment benefit by lessening our use of toxic chemicals, and California companies get a significant boost into markets that are rapidly expanding." Business executives praised the regulations as providing "an orderly transition to safer materials and products" and "promoting a healthy economy, healthy environment and healthy people."

Others don't see it that way. At a public hearing last month, a representative of the Association of Global Automakers warned that the regulations will result in the supply of older replacement parts being disrupted, and "consumers' warrantees or repairs may not be able to be fulfilled."

Pointing to conflicts with federal regulations, an attorney representing members of the construction, home appliance and aircraft industry said the provisions would result "ultimately to the detriment of California's economy by encouraging businesses both large and small to exit California for a more predictable business climate."

Enter state Sen. Michael Rubio, D-Shafter (Kern County), incoming chairman of the Senate Committee on Environmental Quality.

In a letter to Brown, signed by 16 fellow Democrats, Rubio called for halting the "open-ended, virtually unlimited in scope" regulations "until a robust economic impact study is completed," including the number of businesses affected, the costs entailed and jobs endangered (or created).

Rubio said an analysis conducted by the Department of Toxic Substances Control left more questions than answers, and he cites another state law to back up his case. That would be SB617, signed last year by Brown, requiring a stricter cost-benefit analysis before new regulations are promulgated.

Read more from the original source:
Lawmakers seek 'green chemistry' delay

Biotech Industry Look to Benefit From New Act Designed to Promote R&D Joint Ventures

NEW YORK, NY--(Marketwire - Oct 4, 2012) - The Biotechnology Industry has seen increased investor interest in 2012 as it continues to impress with strong gains. The iShares NASDAQ Biotechnology Index ETF (IBB) has gained over 35 percent this year, more than double the S&P 500 Index's gain of 15 percent. New legislation, increased mergers & acquisition activity as a result of major patent expirations have all been contributing factors to industry's rapid rise in 2012. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on AspenBio Pharma, Inc. ( NASDAQ : APPY ) and Keryx Biopharmaceuticals ( NASDAQ : KERX ).

Access to the full company reports can be found at:

http://www.FiveStarEquities.com/APPY

http://www.FiveStarEquities.com/KERX

The Biotechnology Industry Organization (BIO) has recently praised the introduction of the High Technology Small Business Research Incentives Act. The new legislation would allow investors of joint venture R&D projects to utilize the losses and tax credits.

"Through the tax code, Congress historically has provided opportunities that encourage private investment in pre-revenue, R&D-intensive companies. The early growth of the biotech industry in the 1980s was due in part to the ability of investors to support projects aimed at finding new cures and treatments through similar joint ventures. This legislation will help spur greater private investment in biotech and other R&D intensive industries," BIO's President and CEO Jim Greenwood said in a statement.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

AspenBio Pharma is an in vitro diagnostic company focused on the clinical development and commercialization of its blood-based appendicitis test. The company plans to initiate a pivotal study in the fourth quarter of 2012 for its blood-based appendicitis test.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex, an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.FiveStarEquities.com/disclaimer

Read the original:
Biotech Industry Look to Benefit From New Act Designed to Promote R&D Joint Ventures

Review: 'Bitter Seeds' of farmer suicides

Bitter Seeds

Eco documentary. Directed by Micha Peled. (Not rated. 88 minutes.)

"Bitter Seeds," a poignant and insightful look into the human suffering caused by agricultural bioengineering, features an unlikely but appealing protagonist to tell its story about a global phenomenon.

Manjusha Amberwar is 18 years old and lives in central India, the site of a shocking wave of suicides, including her father's. She wants to be a journalist (against all odds for a village girl) and begins to investigate the reasons behind the crisis for the local newspaper.

Her journey, and that of her relatives, is the thread of a well-told story about how the U.S.-based Monsanto Co. persuaded often illiterate farmers to use its genetically altered (and more expensive) seeds, instead of relying on the conventional (and effective) ones that villagers had used for eons.

Unfortunately, the kind of seeds that may work for massive agricultural companies do not always work for small family farms, which don't have the resources to provide the necessary irrigation, fertilizer and pesticides to make their seed investment pay off. Farmers often go bankrupt and lose their land - a big problem in a world where 50 percent of the people are farmers, and where the use of genetically modified seeds is becoming more widespread.

This film doesn't provide a lot of bars or charts or fancy graphics. Just cue cards to give us perspective. And surprisingly beautifully shot scenes of an intimate family drama that takes place over a season of growing cotton. From time to time, Monsanto officials (straight out of central casting) appear, and you can almost see their noses growing as they rationalize the suicides and extol the virtues of their (very profitable) seeds.

One of my favorite things about the movie is that director Micha Peled (who also helmed "China Blue" and "Store Wars: When Walmart Comes to Town") does not resort to doomsday talk or hysterics. This is not a dreary film: Underneath it all is a strong sense of humanity.

Continued here:
Review: 'Bitter Seeds' of farmer suicides

Zacks Rank Anatomy of Success: TCBI

We talk all the time about how the Zacks Rank can get you into the winningest stocks. In this article (and future 'Zacks Rank Anatomy of Success' articles), we'll go beyond just telling you how the Zacks Rank can get you into the best performers, but actually show you, on a chart, so you can see for yourself.

Whether it's a widely known large-cap stock, little known small-cap stock or somewhere in between, the steps to success are the same.

And while the Zacks Rank is a great short-term indicator for finding the most profitable opportunities over a 1-3 month period, you'll also see (as illustrated below) how it can keep you in on the strongest ones for even bigger gains.

Example: Texas Capital Bancshares

Texas Capital Bancshares (TCBI) is a mid-cap blend (growth and value) stock in the Financial Industry. As a regional bank headquartered in Texas, it's not one of those stocks with a national presence or name recognition. In fact, if you didn't live in Texas, you'd be hard pressed to have ever heard of it.

But many of your favorite stocks were likely new to you at some point. The trick is getting these onto your radar screen so you become aware of them. And having the confidence that when they do, they are worthy of taking a position.

One of the best ways to tell if a stock is hot or if it's not is to see if it has a Zacks #1 Rank and rising earnings estimates.

On January 6, 2012, TCBI was identified as one of the hot ones when it received a Zacks #1 Rank (Strong Buy). Even as many investors were still shunning financial stocks, this one distinguished itself from the others and was poised to outperform.

Between 1/6/12, when it was trading at $31.77, and 8/31/12, when it closed at $46.02, TCBI rewarded investors with a 44.85% gain in just 8 short months compared to the market's 10.08%.

During that time, their 12 Month Forward Earnings Estimates climbed from $2.24 to $3.12, which was a 39.28% increase and the clear catalyst for TCBI's commensurately stellar gains.

Read this article:
Zacks Rank Anatomy of Success: TCBI

Skull Fragment Shows Earliest Evidence Of Human Meat Consumption

October 4, 2012

A fragment of a child's skull discovered at Olduvai Gorge, Tanzania, shows the oldest known evidence of anemia caused by a nutritional deficiency. Credit: Dominguez-Rodrigo M, Pickering TR, Diez-Martin F, Mabulla A, Musiba C, et al. (2012)

Lawrence LeBlond for redOrbit.com Your Universe Online

New evidence indicates that early humans were meat eaters, based on a 1.5-million-year-old skull unearthed in Tanzania by Spanish researchers. The skull, that of a child, shows signs of anemia, suggesting a regular diet of meat in early hominids. The finding sheds new light on the evolution of human physiology and brain development.

The skull was found in the Olduvai Gorge in Tanzania and showed signs of nutritional deficiencies commonly caused by a lack of meat in the diet. This finding suggests early man needed meat to thrive, and leads researchers, led by Manuel Domnguez-Rodrigo from Complutense University, Madrid, to believe our ancestors began eating meat much earlier in history than previously believed.

Previous studies have shown that early hominids ate meat, but whether it was a regular part of their diet or only occasionally consumed was not known. Dominguez-Rodrigo and his team suggest the bone lesions present in this skull fragment provide support for the idea that early humans needed to maintain a meat-diet or anemia would set in. The bone lesions observed in the child skull fragment shows signs of vitamin-B deficiency.

Nutritional deficiencies, such as anemia, are most common during weaning, when the diet of children change drastically. The authors suggest that the child possibly died at a time when he/she was beginning to eat solid foods lacking meat. And, if the child was breastfed, it is possible the mother may have been nutritionally deficient as well.

Both cases imply that early humans were hunters, and had a physiology adapted to regular meat consumption at least 1.5 million years ago, the authors noted.

Meat eating has always been considered one of the things that made us human, with the protein contributing to the growth of our brains, said Charles Musiba, PhD, associate professor of anthropology at the University of Colorado Denver, who helped make the discovery.

Musiba said evidence in the childs skull fragment shows deficiency in vitamin B12 and B9, indicating meat was cut off during the weaning process. He was not getting the proper nutrients and probably died of malnutrition, he said.

Read the rest here:
Skull Fragment Shows Earliest Evidence Of Human Meat Consumption

DigiPath Provides Affordable Upgrade & Pathology Access to Areas in Need

DigiPath today announces PathTrade, the exchange initiative that provides affordable and innovative digital pathology solutions, while also providing means for underserved communities to access pathology educational and medical experts throughout the world.

Henderson, Nevada (PRWEB) October 04, 2012

PathTrade provides existing telepathology users an affordable means to upgrade discontinued telepathology systems with a DigiPath solution. DigiPath will provide $500 to $5,000 as trade-in credit for upgrading to PathScope and/or PathLive value. Additionally, DigiPath will refurbish system, and deploy system without any additional fees, in communities in need of pathology educational and medical experts. DigiPath has identified many underserved communities in Africa, India, Mideast, Southeast Asia, Caribbean, and South America, for installations in 2012.

DigiPath has been asked numerous times to assist in providing systems in countries of need of pathology expertise, said Steve Barbee, Vice President of DigiPath, Inc., Vice President of DigiPath, Inc. DigiPath is delighted to not only assist our clients in upgrading systems, but in bringing advanced pathology practices to underserved communities worldwide.

Please email info(at)digipath(dot)biz if interested in upgrading your telepathology system for world health benefits.

About DigiPath, Inc.

DigiPath, Inc. provides the next generation of affordable, innovative, and reliable digital pathology solutions. DigiPaths advisors bring over 60 years combined expertise in pioneering digital pathology, implementing over 750 installations at community pathology practices, hospitals, academic medical centers, reference laboratories, biopharma organizations, and life science research institutions worldwide. DigiPath has offices within Kansas, California, Maryland, and Nevada. Please see http://digipath.biz for more details.

SAFE HARBOR STATEMENT

This Press Release may contain certain forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. DigiPath has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect DigiPath's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause DigiPath's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. DigiPath undertakes no obligation to update or provide advice in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.

DigiPath Media Relations DigiPath, inc. (702) 527-2060 Email Information

Excerpt from:
DigiPath Provides Affordable Upgrade & Pathology Access to Areas in Need